Movatterモバイル変換


[0]ホーム

URL:


Prijeđi na sadržaj
Wikipedija
Pretraga

Ruksolitinib

Izvor: Wikipedija
Ruksolitinib
Klinički podaci
Robne markeJakafi, Jakavi
AHFS/Drugs.comMonografija
Identifikatori
CAS broj941678-49-5
ATC kodL01XE18
DrugBankDB08877
ChemSpider[1]25027389
ChEBICHEBI:66919 DaY
ChEMBL[2]CHEMBL1789941 DaY
Hemijski podaci
FormulaC17H18N6 
Mol. masa306,365
SMILESeMolekuli &PubHem
InChI
InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
Key: HFNKQEVNSGCOJV-OAHLLOKOSA-N DaY
Farmakokinetički podaci
Poluvreme eliminacije2,8 h
Farmakoinformacioni podaci
Trudnoća?
Pravni status
Način primeneOralno

Ruksolitinib jeorgansko jedinjenje, koje sadrži 17atomaugljenika i imamolekulsku masu od 306,365Da.[3][4][5][6]

Osobine

[uredi |uredi kod]
OsobinaVrednost
Broj akceptora vodonika4
Broj donora vodonika1
Broj rotacionih veza4
Particioni koeficijent[7] (ALogP)2,9
Rastvorljivost[8] (logS, log(mol/L))-4,8
Polarna površina[9] (PSA,Å2)83,2

Reference

[uredi |uredi kod]
  1. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.  edit
  2. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  3. Cervantes F, Martinez-Trillos A: Myelofibrosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013 May;14(7):873-84. doi: 10.1517/14656566.2013.783019. Epub 2013 Mar 21.PMID23514013
  4. Yang LP, Keating GM: Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27. doi: 10.2165/11209340-000000000-00000.PMID23061804
  5. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.  edit
  6. David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.  edit
  7. Ghose, A.K., Viswanadhan V.N., and Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A 102: 3762-3772. DOI:10.1021/jp980230o. 
  8. Tetko IV, Tanchuk VY, Kasheva TN, Villa AE. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488-1493. DOI:10.1021/ci000392t. PMID 11749573.  edit
  9. Ertl P., Rohde B., Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714-3717. DOI:10.1021/jm000942e. PMID 11020286.  edit

Literatura

[uredi |uredi kod]

Vanjske veze

[uredi |uredi kod]
Portal Medicina
Portal Hemija
Ruksolitinib naWikimedijinoj ostavi
Izvor:https://sh.wikipedia.org/w/index.php?title=Ruksolitinib&oldid=42300066
Kategorije:

[8]ページ先頭

©2009-2025 Movatter.jp